Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid ...
The months ahead will determine whether they will become turning points or missed opportunities. Cancer does not wait for GDP targets, and patients cannot wait for promises to turn into action ...
In this study, researchers reported on 10-year follow-up of a phase 3 trial comparing surgery to chemoradiation boost in resectable, advanced NSCLC.
Experts discuss how treatment strategies for NSCLC differ between resectable and metastatic disease, emphasizing a multimodal, curative approach in early-stage cancer versus personalized systemic ...
The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.
Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as a ...
ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe ...
OncoHost, a technology company transforming precision oncology through proteomics and AI, today announced the publication of a new study in the Journal of Pharmaceutical and Biomedical Analysis (JPBA) ...
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT ...
Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 3:15 PM ESTCompany ParticipantsJean-Charles Soria - Senior Vice ...
ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early efficacy and manageable safety. Learn more about IBRX stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results